
Murray International Trust PLC 17
Strategic Report
Governance
Overview Portfolio General Corporate Information Financial Statements
British American Tobacco (BAT)
BAT delivered a notably strong performance in 2025, a
year characterised by strategic execution following
several years of significant investment. Revenue rose
around 2% on a constant currency basis, slightly ahead of
expectations. A key highlight was the US business, which
returned to both revenue and profit growth for the first
time since 2022, supported by stabilising combustible
market share and the withdrawal of the proposed
menthol ban.
BAT’s smokeless portfolio continued to scale, reaching
18.2% of Group revenue. Nicotine pouches, particularly
the Velo brand, were standout performers, growing more
than 40% in the first half. Strong cash conversion, above
95%, enabled the company to expand its 2025 share
buyback to £1.1 billion. Meanwhile, productivity initiatives
remained firmly on track, with savings expected to exceed
£1.2 billion by year-end, helping to offset inflationary
pressures.
Stocks detracting from performance in 2025
Given the year’s volatility and the portfolio’s diversified
positioning, it is inevitable that not all holdings delivered
positive returns. What matters is whether periods of
weakness challenge the underlying investment thesis or
instead create opportunities to add capital at more
attractive valuations. In 2025, a clearer pattern emerged:
healthcare and alcohol producers were among the
weakest performers.
Diageo
Diageo’s share price struggled in 2025 as a combination of
macroeconomic, category specific, and operational
headwinds weighed on performance. Weak consumer
confidence in key markets, particularly the US and China,
was a significant drag, with stretched household budgets
and cautious spending reducing demand for premium
spirits. In the US, competitive pressures in tequila, ongoing
destocking, and tough comparisons following prior
restocking of brands such as Don Julio added further
strain. These challenges were compounded by broader
premium-spirits weakness linked to the cost of living
backdrop, shifting consumer behaviour, and concerns
that weight loss drugs may dampen alcohol consumption.
Rising inflation and geopolitical uncertainty contributed to
a global slowdown in spirits demand, prompting Diageo to
withdraw its medium-term organic growth guidance
amid an uncertain recovery trajectory. Tariff related
pressures in 2025 added to difficulties, increasing costs
and weighing on sentiment as US trade tensions
escalated. Currency volatility, elevated inventories, and
leadership instability following CEO changes also acted as
headwinds.
Despite these challenges, we believe the business
continues to exhibit the core characteristics underpinning
the investment thesis. We see long-term opportunity in the
global scotch whisky market, particularly in the US and
China, and continue to value Diageo's broad geographic
footprint and the strength of its brand portfolio. We also
believe the company is well placed to innovate in
response to shifting consumer tastes, particularly through
low- and no-alcohol offerings and ready-to-drink formats.
While performance has been disappointing and
frustrating to date, we have used share price weakness to
add selectively to the position, as we believe current levels
offer long-term value.
Pernod Ricard
Pernod Ricard faced a challenging 2025, affected by
many of the same pressures that weighed on Diageo.
Organic net sales declined for the fiscal year, driven by
pronounced weakness in the US, China, and Global Travel
Retail - three of its four strategic “must win” markets. In the
US, softer spirits demand and ongoing distributor inventory
adjustments held back performance, while persistent US
tariffs under the current administration risked costing the
Group €35 million. China proved an even larger drag: sales
fell 21% amid weak demand for Scotch and the effective
suspension of Martell shipments in the second half.
Despite these headwinds, Pernod Ricard maintained
strong cost discipline, expanding organic operating
margins and advancing its long term €1 billion efficiency
programme. As with Diageo, we do not believe Pernod
Ricard’s investment thesis is broken. We have therefore
added to the position during periods of share price
weakness, where we see long-term value emerging
despite near-term pressures.
Bristol Myers Squibb
Bristol Myers Squibb faced significant challenges in 2025,
as accelerating erosion from non-branded generic
competition and continued US regulatory and pricing
uncertainty weighed heavily on sentiment. The primary
pressure point was the decline of the Legacy Portfolio:
cancer therapies such as Revlimid, Pomalyst, Sprycel, and
Abraxane experienced ongoing volume and pricing
headwinds.
We used the weakness in Bristol Myers Squibb’s share
price to add to the position, as the company’s Growth
Portfolio continued to expand. Key products including